Effects of statins on dopamine loss and prognosis in Parkinson’s disease
Open Access
- 4 August 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 144 (10), 3191-3200
- https://doi.org/10.1093/brain/awab292
Abstract
Statins are more widely used not only for the primary and secondary prevention of cardiovascular disease by blocking cholesterol biosynthesis but also for the potential neuroprotective agents during neurological disorders due to their pleiotropic effects. In this study, we investigate whether the previous use of statins affect baseline nigrostriatal dopamine loss at the time of diagnosis and longitudinal motor and cognitive outcomes in patients with Parkinson’s disease. Five hundred drug-naïve patients with Parkinson’s disease who underwent dopamine transporter imaging were classified into two groups according to the prior use of statins: patients with and without statin use. Multivariate linear regression was used to determine intergroup differences in dopamine transporter availability. We evaluated the longitudinal changes in levodopa-equivalent dose and dementia conversion between the groups using a linear mixed model and survival analysis, respectively. In addition, mediation analysis was applied to examine the effect of total cholesterol. Patients with Parkinson’s disease treated with statins had a lower baseline dopamine transporter availability in the anterior (2.13 ± 0.55 versus 2.37 ± 0.67; P = 0.002), posterior (1.31 ± 0.43 versus 1.49 ± 0.54; P = 0.003) and ventral putamina (1.40 ± 0.39 versus 1.56 ± 0.47; P = 0.002) than that in matched patients with Parkinson’s disease without statins. After adjusting for age at symptom onset, sex, disease duration and vascular risk factors, linear regression models showed that a previous treatment with statins remained significantly and independently associated with more severely decreased dopamine transporter availability in the anterior putamen (Beta = −0.140, P = 0.004), posterior putamen (Beta = −0.162, P = 0.001) and ventral putamen (Beta = −0.140, P = 0.004). A linear mixed model revealed that patients with Parkinson’s disease being treated with statins had a faster longitudinal increase in levodopa-equivalent dose than those without. A survival analysis showed that the rate of dementia conversion was significantly higher in patients with Parkinson’s disease with statins (hazard ratio, 2.019; 95% confidence interval, 1.108–3.678; P = 0.022) than those without. Mediation analyses revealed that the effect of statin treatment on baseline dopamine transporter availability and longitudinal outcome was not mediated by total cholesterol levels. This study suggests that statin use may have a detrimental effect on baseline nigrostriatal dopamine degeneration and long-term outcomes in patients with Parkinson’s disease.Keywords
Funding Information
- Korea Health Technology R&D project
- Korean Healthy Industry Development Institute
- KHIDI
- Ministry of Health & Welfare, Republic of Korea (HU21C0053)
This publication has 49 references indexed in Scilit:
- The Effect of HMG-CoA Reductase Inhibitors on Cognition in Patients With Alzheimer's Dementia: A Prospective Withdrawal and Rechallenge Pilot StudyThe American Journal of Geriatric Pharmacotherapy, 2012
- Inhibition of neuronal cholesterol biosynthesis with lovastatin leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniolJournal of Neurochemistry, 2011
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Clinical measures of progression in Parkinson's diseaseMovement Disorders, 2009
- Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort studyNeurology, 2008
- Statin use and the risk of Parkinson diseaseNeurology, 2008
- Statins reduce neuronal α‐synuclein aggregation in in vitro models of Parkinson’s diseaseJournal of Neurochemistry, 2008
- Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD ratsNeuroscience Letters, 2006
- Decreased Cholesterol Biosynthesis in Fibroblasts from Patients with Parkinson DiseaseBiochemical Medicine and Metabolic Biology, 1993
- A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imagingJournal of the Neurological Sciences, 1993